The cancer drug developer and Stanford spinout floated at the top of its range in an offering that could reach $129m.

Health insurance platform Bind has raised funding from a consortium featuring strategic partner UnitedHealthcare and Ascension Ventures.

The cancer therapy developer has closed an $11.1m series A round featuring M Ventures and seed-stage backer Novo Seeds.

The GV-backed cancer drug developer floated at the top of its range in an offering that could reach $129m.

Tasly Pharmaceuticals contributed to a series C round for the immunotherapy developer, a year after backing its $150m series B.

Precision oncological diagnostics developer Clearbridge BioMedics is planning to float, almost a decade after it was spun out from National University of Singapore and Smart Centre.

The SoftBank-backed genetic liquid biopsy technology developer has raised a nine-figure renminbi amount in a Shenzhen Capital-led round.

CorInnova and Intelligent Implants have both secured funding after participating in the JLabs@TMC incubator.